A Survey of the Neuro-Oncology Landscape

키워드

참고문헌 (55)

1. Lukas RV, "Treatment of brain metastases", Oncology, 87, pp.321~329 (2014)[DOI]
2. Lukas RV, "Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice", Neuro-Oncol Pract (2016)[DOI]
3. Desjardins A, "Vaccine therapy, oncolytic viruses, and gliomas", Oncology (Williston Park), 30, pp.211~218 (2016)
4. Patchell RA, "A randomized trial of surgery in the treatment of single metastases to the brain", N Engl J Med, 322, pp.494~500 (1990)[DOI]
5. Coburger J, "Comparison of navigated transcranial magnetic stimulation and functional magnetic resonance imaging for preoperative mapping in rolandic tumor surgery", Neurosurg Rev, 36, pp.65~75 (2013)[DOI]
6. Nimsky C, "Merits and limits of tractography techniques for the uninitiated", Adv Tech Stand Neurosurg, 43, pp.37~60 (2016)
7. Brastianos PK, "Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets", Cancer Discov, 5, pp.1164~1177 (2015)[DOI]
8. Missios S, "Renaissance of laser interstitial thermal ablation", Neurosurg Focus, 38, pp.E13~ (2015)
9. Sharma M, "Laser interstitial thermal therapy in the management of brain metastasis and radiation necrosis after radiosurgery: an overview", Expert Rev Neurother, 16, pp.223~232 (2016)[DOI]
10. Patel P, "Intracranial MR-guided laser-induced thermal therapy: single-center experience with the Visualase thermal therapy system", J Neurosurg, 125, pp.853~860 (2016)[DOI]
11. Carpentier A, "Laser thermal therapy: real-time MRI-guided and computer- controlled procedures for metastatic brain tumors", Lasers Surg Med, 43, pp.943~950 (2011)[DOI]
12. Ivan ME, "Laser ablation of newly diagnosed malignant gliomas: a metaanalysis", Neurosurgery, 79(Suppl 1), pp.S17~S23 (2016)[DOI]
13. Lee I, "Stereotactic laser interstitial thermal therapy for recurrent high-grade gliomas", Neurosurgery, 79(Suppl 1), pp.S24~S34 (2016)[DOI]
14. Louis DN, "WHO Classification of Tumours of the Central Nervous System WHO", IARC Classification of Tumours, 2016
15. Louis DN, "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary", Acta Neuropathol, 131, pp.803~820 (2016)[DOI]
16. Dang L, "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate", Nature, 462, pp.739~744 (2009)[DOI]
17. Zhao S, "Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-<TEX>$1{\alpha}$<", TEX>, 2009, pp.324, 261~265
18. Dang L, "IDH mutations in cancer and progress toward development of targeted therapeutics", Ann Oncol, 27, pp.599~608 (2016)[DOI]
19. Frezza C, "IDH1 mutations in gliomas: when an enzyme loses its grip", Cancer Cell, 17, pp.7~9 (2010)[DOI]
20. Sanson M, "Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas", J Clin Oncol, 27, pp.4150~4154 (2009)[DOI]
21. Sturm D, "Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma", Cancer Cell, 22, pp.425~437 (2012)[DOI]
22. Ceccarelli M, "Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma", Cell, 164, pp.550~563 (2016)[DOI]
23. Yan H, "IDH1 and IDH2 mutations in gliomas", N Engl J Med, 360, pp.765~77. (2009)[DOI]
24. Chen H, "Mutant IDH1 and seizures in patients with glioma", Neurology, 88, pp.1805~1813 (2017)[DOI]
25. Kuhnt D, "Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance", Neuro Oncol, 13, pp.1339~1348 (2011)[DOI]
26. Napolitano M, "Glioblastoma surgery with and without intraoperative MRI at 3.0T", Neurochirurgie, 60, pp.143~150 (2014)[DOI]
27. Herrera SR, "Use of transparent plastic tubular retractor in surgery for deep brain lesions: a case series", Surg Technol Int, 19, pp.47~50 (2010)
28. Recinos PF, "Use of a minimally invasive tubular retraction system for deep-seated tumors in pediatric patients", J Neurosurg Pediatr, 7, pp.516~521 (2011)[DOI]
29. Bloch O, "Heatshock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial", Neuro Oncol, 16, pp.274~279 (2014)[DOI]
30. Lawler SE, "Oncolytic viruses in cancer treatment: a review", JAMA Oncol, 3, pp.841~849 (2017)[DOI]
31. Desjardins A, "Patient survival on the dose escalation phase of the Oncolytic Polio", Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls, 2016, pp.34(suppl 15), 2061~
32. Chiocca EA, "Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: tolerability and survival in recurrent glioblastoma", J Clin Oncol, 35(suppl 15), pp.2044~ (2017)[DOI]
33. Ostertag D, "ATIM-17. Investigation of anti-tumor cellular immune response elicited by Toca 511 & Toca FC therapy in a recurrent HGG phase 1 trial", Neuro Oncol, 18(suppl 6), pp.vi21~ (2016)
34. Huang TT, "Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide- sensitive glioblastoma model", Cancer Gene Ther, 20, pp.544~551 (2013)[DOI]
35. Ahmed AU, "A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy", J Natl Cancer Inst, 105, pp.968~977 (2013)[DOI]
36. Ahmed AU, "Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors", Methods Mol Biol, 797, pp.97~109 (2012)
37. Ahmed AU, "Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma", Mol Ther, 19, pp.1714~1726 (2011)[DOI]
38. Cloughesy TF, "Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC", J Clin Oncol, 35(Suppl 15), pp.e13504~ (2017)
39. Hottinger AF, "Tumor treating fields: a novel treatment modality and its use in brain tumors", Neuro Oncol, 18, pp.1338~1349 (2016)[DOI]
40. Stupp R, "LTBK-01: Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma", Neuro Oncol, 18(suppl 6), pp.i1~ (2016)[DOI]
41. Stupp R, "Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial", JAMA, 314, pp.2535~2543 (2015)[DOI]
42. Reardon DA, "IMCT-08 ReACT: long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma", Neuro Oncol, 17, pp.v109~ (2015)
43. Weller M, "Rindopepimut with temozolomide in patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, doubleblind, international phase 3 trial", Lancet Oncol, 18, pp.1373~1385 (2017)[DOI]
44. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)[DOI]
45. Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma", N Engl J Med, 372, pp.2521~2532 (2015)[DOI]
46. Powles T, "MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer", Nature, 515, pp.558~562 (2014)[DOI]
47. Omuro A, "ATIM-16. Nivolumab combined with radiotherapy with or without temozolomide in patients with newly diagnosed glioblastoma: results from phase 1 safety cohorts in CHECKMATE 143", Neuro Oncol, 18(suppl 6), pp.vi21~ (2016)
48. Reardon DA, "ATIM-35. Results of the phase IB KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM)", Neuro Oncol, 18(suppl 6), pp.vi25~vi26 (2016)
49. Sahebjam S, "ATIM-15. A phase I trial of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas", Neuro Oncol, 18(suppl 6), pp.vi21~ (2016)
50. Dixit K, "ATIM-10. Phase I", II trial of radiation therapy, temozolomide and pembrolizumab followed by temozolomide and pembrolizumab in patients with newly diagnosed glioblastoma, 2016, pp.18(suppl 6), vi19~
51. Reardon DA, "OS10.3 Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143", Neuro-Oncology, 19(suppl 3), pp.iii21~ (2017)
52. ) in patients with glioblastoma (GBM): results forcohort B (dur monotherapy), bevacizumab (bev) naive patients withrecurrent GBM, "Neuro Oncol", 2016, vi18~
53. Lukas RV, "Clinical activity and safety of atezolizumab (anti-PDL1) in patients with glioblastoma (GBM)", 20th Ann Sci Meeting Edu Day Soc Neuro-Oncol (2015), Society for Neuro-Oncology
54. Zakharia Y, "IMCT-21 Updates on phase 1B", 2 combination study of the IDO pathway ihibitor indoximod with temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors, 2015, pp.17, v112~
55. Butowski N, "Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study", Neuro Oncol, 18, pp.557~564 (2016)[DOI]

관련 논문AI추천